TISIDB

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00505 HMG (high mobility group) box
Function	Transcriptional activator. Binds specifically to the DNA sequence 5'-AACAAT-3'. Plays a key role in several developmental processes, including neurogenesis and skeleton formation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001701 in utero embryonic development GO:0001708 cell fate specification GO:0002062 chondrocyte differentiation GO:0002262 myeloid cell homeostasis GO:0007507 heart development GO:0007517 muscle organ development GO:0009791 post-embryonic development GO:0010001 glial cell differentiation GO:0014706 striated muscle tissue development GO:0016202 regulation of striated muscle tissue development GO:0016458 gene silencing GO:0021778 oligodendrocyte cell fate specification GO:0021779 oligodendrocyte cell fate commitment GO:0021780 glial cell fate specification GO:0021781 glial cell fate commitment GO:0030099 myeloid cell differentiation GO:0030218 erythrocyte differentiation GO:0032330 regulation of chondrocyte differentiation GO:0032332 positive regulation of chondrocyte differentiation GO:0034101 erythrocyte homeostasis GO:0035051 cardiocyte differentiation GO:0042063 gliogenesis GO:0042692 muscle cell differentiation GO:0045165 cell fate commitment GO:0045843 negative regulation of striated muscle tissue development GO:0048634 regulation of muscle organ development GO:0048635 negative regulation of muscle organ development GO:0048708 astrocyte differentiation GO:0048709 oligodendrocyte differentiation GO:0048738 cardiac muscle tissue development GO:0048821 erythrocyte development GO:0048863 stem cell differentiation GO:0048872 homeostasis of number of cells GO:0051146 striated muscle cell differentiation GO:0051147 regulation of muscle cell differentiation GO:0051148 negative regulation of muscle cell differentiation GO:0051153 regulation of striated muscle cell differentiation GO:0051154 negative regulation of striated muscle cell differentiation GO:0051216 cartilage development GO:0055007 cardiac muscle cell differentiation GO:0055024 regulation of cardiac muscle tissue development GO:0055026 negative regulation of cardiac muscle tissue development GO:0060537 muscle tissue development GO:0061035 regulation of cartilage development GO:0061036 positive regulation of cartilage development GO:0061448 connective tissue development GO:0061515 myeloid cell development GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0072497 mesenchymal stem cell differentiation GO:1901861 regulation of muscle tissue development GO:1901862 negative regulation of muscle tissue development GO:1905207 regulation of cardiocyte differentiation GO:1905208 negative regulation of cardiocyte differentiation GO:2000725 regulation of cardiac muscle cell differentiation GO:2000726 negative regulation of cardiac muscle cell differentiation GO:2000736 regulation of stem cell differentiation GO:2000738 positive regulation of stem cell differentiation GO:2000739 regulation of mesenchymal stem cell differentiation GO:2000741 positive regulation of mesenchymal stem cell differentiation
Molecular Function	GO:0046982 protein heterodimerization activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-3769402: Deactivation of the beta-catenin transactivating complex R-HSA-162582: Signal Transduction R-HSA-195721: Signaling by Wnt R-HSA-201681: TCF dependent signaling in response to WNT

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SOX6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SOX6 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
18224680	Glioma	Promote immunity (T cell function); essential for immunotherapy	Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Following SOX6-DNA vaccination, CTLs specific for SOX6-expressing glioma cells were induced, while normal autologous-cells that had restrictedly expressed SOX6 during embryogenesis were not destroyed.

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SOX6 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SOX6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.702	0.291
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.084	0.366
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.402	0.735
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.308	0.568
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.336	0.845
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.252	0.88
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.045	0.96
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.562	0.732
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.757	0.676
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-1.034	0.234
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.31	0.259
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.22	0.29

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SOX6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOX6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOX6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOX6. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOX6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SOX6 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SOX6 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SOX6
Name	SRY (sex determining region Y)-box 6
Aliases	HSSOX6; SOXD; SRY-box containing gene 6; Transcription factor SOX-6
Chromosomal Location	11p15.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SOX6 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SOX6